These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms. Nutho B; Mahalapbutr P; Hengphasatporn K; Pattaranggoon NC; Simanon N; Shigeta Y; Hannongbua S; Rungrotmongkol T Biochemistry; 2020 May; 59(18):1769-1779. PubMed ID: 32293875 [TBL] [Abstract][Full Text] [Related]
3. Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel Sencanski M; Perovic V; Pajovic SB; Adzic M; Paessler S; Glisic S Molecules; 2020 Aug; 25(17):. PubMed ID: 32842509 [TBL] [Abstract][Full Text] [Related]
5. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection. Martorana A; Gentile C; Lauria A Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574 [TBL] [Abstract][Full Text] [Related]
6. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease. Akaji K; Konno H Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349 [TBL] [Abstract][Full Text] [Related]
7. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Froggatt HM; Heaton BE; Heaton NS J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534 [TBL] [Abstract][Full Text] [Related]
8. Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors. Jiménez-Alberto A; Ribas-Aparicio RM; Aparicio-Ozores G; Castelán-Vega JA Comput Biol Chem; 2020 Oct; 88():107325. PubMed ID: 32623357 [TBL] [Abstract][Full Text] [Related]
9. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Kumar Y; Singh H; Patel CN J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274 [TBL] [Abstract][Full Text] [Related]
10. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy. Goyal B; Goyal D ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186 [TBL] [Abstract][Full Text] [Related]
11. Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design. Meyer-Almes FJ Comput Biol Chem; 2020 Oct; 88():107351. PubMed ID: 32769050 [TBL] [Abstract][Full Text] [Related]
12. Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy. Mohammad T; Shamsi A; Anwar S; Umair M; Hussain A; Rehman MT; AlAjmi MF; Islam A; Hassan MI Virus Res; 2020 Oct; 288():198102. PubMed ID: 32717346 [TBL] [Abstract][Full Text] [Related]
13. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs. Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297 [TBL] [Abstract][Full Text] [Related]
14. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors. He J; Hu L; Huang X; Wang C; Zhang Z; Wang Y; Zhang D; Ye W Int J Antimicrob Agents; 2020 Aug; 56(2):106055. PubMed ID: 32534187 [TBL] [Abstract][Full Text] [Related]
15. High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2. Olubiyi OO; Olagunju M; Keutmann M; Loschwitz J; Strodel B Molecules; 2020 Jul; 25(14):. PubMed ID: 32668701 [TBL] [Abstract][Full Text] [Related]
16. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study. Wang J J Chem Inf Model; 2020 Jun; 60(6):3277-3286. PubMed ID: 32315171 [TBL] [Abstract][Full Text] [Related]
18. Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2. Tripathi PK; Upadhyay S; Singh M; Raghavendhar S; Bhardwaj M; Sharma P; Patel AK Int J Biol Macromol; 2020 Dec; 164():2622-2631. PubMed ID: 32853604 [TBL] [Abstract][Full Text] [Related]
19. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus. Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A Molecules; 2020 May; 25(11):. PubMed ID: 32485894 [TBL] [Abstract][Full Text] [Related]
20. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study. Hosseini FS; Amanlou M Life Sci; 2020 Oct; 258():118205. PubMed ID: 32777300 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]